AbbVie (ABBV) Stock Chart - Revenue & Earnings | Quarter Chart

๐Ÿ“Š Income Statement โ–ฒ

Revenue by Product

SKYRIZIRINVOQH U M I R ABotox TherapeuticVraylarImbruvicaVENCLEXTAOther ProductsBotox CosmeticMAVYRETUbrelvyOther AestheticsQuliptaOther Eye CareJuvederm CollectionLinzess/ConstellaOzurdexLumigan/GanfortDuodopaOther NeuroscienceAlphagan/Combigan
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue by Geography

UNITED STATESNon-US
06B12B19B25B31B38B44B50BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
06B12B19B25B31B38B44B50BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development ExpensesSelling General And Administrative ExpensesOther Expenses
01B2B4B5B6B8B9B10BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
0875M2B3B4B4B5B6B7BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

EPSEPS Diluted
001122233Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue Variation (%)

Revenue Variation
-20-15-10-505101520Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
02505007501K1K2K2K2KQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
02581012151820Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
0815223038455260Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
088175262350438525612700Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
01B2B3B4B6B7B8B9BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
02581012151820Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
๐Ÿ’ฐ Cash Flow Statement โ–ฒ

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash Flow to Debt Ratio

Cash At End Of Period
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
๐Ÿฆ Balance Sheet โ–ผ
๐Ÿ“ˆ Key Metrics โ–ผ

AbbVie (ABBV) quarterly earnings & revenue

AbbVie (ABBV) reported revenue of $15.00B for Q1 2026, up 12.4% year-over-year, with net income of $699.00M and diluted EPS of $0.39.

Over the last four reported quarters, AbbVie generated $62.82B in revenue and $3.64B in net income.

AbbVie's next earnings report is scheduled for July 31, 2026 before market open; analysts estimate EPS of $3.76.

AbbVie quarterly results

Fiscal quarterRevenueRevenue YoYNet incomeEPS (diluted)
Q1 2026$15.00B+12.4%$699.00M$0.39
Q4 2025$16.62B+10.0%$1.82B$1.02
Q3 2025$15.78B+9.1%$186.00M$0.10
Q2 2025$15.42B+6.6%$938.00M$0.53
Q1 2025$13.34B+8.4%$1.29B$0.72
Q4 2024$15.10B+5.6%$-22.00M$-0.02
Q3 2024$14.46B+3.8%$1.56B$0.88
Q2 2024$14.46B+4.3%$1.37B$0.77

๐Ÿ“ˆ Analysts estimate ABBV EPS of $3.76 for the upcoming quarter. See AbbVie revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

AbbVie (ABBV) โ€” frequently asked questions

When does AbbVie (ABBV) report earnings next?

AbbVie is expected to report earnings on July 31, 2026 before market open. Analysts estimate EPS of $3.76.

What was ABBV's revenue last quarter?

AbbVie reported revenue of $15.00B in Q1 2026, up 12.4% from the same quarter a year earlier.

What was ABBV's EPS last quarter?

AbbVie reported diluted EPS of $0.39 in Q1 2026.

Is AbbVie profitable?

AbbVie is currently profitable, with $3.64B in net income over the last four reported quarters.

Compare with other Healthcare companies: Eli Lilly (LLY) ยท Johnson & Johnson (JNJ) ยท UnitedHealth (UNH) ยท Roche (ROG.SW) ยท Merck (MRK) ยท Novartis (NVS)